Press Release • Press Release • Press Release • Press Release • Press Release

Vivimed

For Immediate Release

March 8, 2021

VIVIMED PRODUCT APPROVALS

Hyderabad, India, March 8, 2021 – Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that it received approval for 2 products from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad

1. **PRODUCT:** Bilastin tablets(Brand Name FLUSTIN)- is a second-generation antihistamine (a selective histamine H1 receptor antagonist
   USES: It is used in the treatment of allergic Rhino conjunctivitis and Urticaria (hives).

2. **PRODUCT:** Orzole combi
   USES: Ofloxacin + Ornidazole is used in the treatment of bacterial & parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections

*** *** ***

Commenting on the Approval, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "We are very excited to receive approval to Vivimed's own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy" .

For further information on Vivimed, visit www.vivimedlabs.com

*** *** ***

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

Company Contact:
Kopparthi Yugandhar
Company Secretary & Compliance officer
Vivimed Labs Limited (CIN No: L02411KA1988PLC009465)
Corporate office: Northend Complex, Road No.2,Banjara Hills, Hyderabad, India
Phone: 040-66086608, Email: yugandhar.kopparthi@vivimedlabs.com

For VIVIMED LABS LTD.

K. YUGANDHAR
Company Secretary
ACS No. 19315